ÌÇÐÄvlog´«Ã½

Aptamers Market Analysis

The Global Aptamers Market size is estimated at USD 1.79 billion in 2024, and is expected to reach USD 3.52 billion by 2029, at a CAGR of 14.49% during the forecast period (2024-2029).

Some of the factors that are driving the market growth include the high advantage of aptamers compared to antibodies, advancements in the field of aptamer development technologies, and growing investment in companies and research institutes.

Numerous advantages offered by these small molecules in comparison to established antibodies have also led to higher demand for these molecules across a diverse range of medical applications. They are chemically synthesized, which eliminates batch-to-batch variation and demands less time for development. Along with this, continuous advancement in technologies is expected to stimulate market growth. According to a research study published in Nature Review in June 2024, aptamers provide distinct advantages, such as reduced production costs, enhanced thermal stability, and an extended shelf life. In contrast to antibodies, which often face batch-to-batch variability and demand intricate production methods involving animals, aptamers can be swiftly and consistently synthesized using in vitro techniques like SELEX (Systematic Evolution of Ligands by Exponential Enrichment). Furthermore, aptamers exhibit remarkable flexibility and adaptability, enabling them to bind to a diverse array of targets, from small molecules to proteins. Their compact size not only facilitates improved tissue penetration but also minimizes toxicity. Thus, such benefits associated with aptamers over the antibodies are expected to increase its demand over the forecast period.

The market players are adopting various strategies, such as product launches, developments, collaborations, partnerships, and expansions, to increase their market share. For instance, in June 2023, Zentek Ltd. announced that its aptamer platform, globally licensed exclusively from McMaster University Canada showed promise as a potential prophylactic or therapeutic for SARS-CoV-2 in pre-clinical animal models. In multiple trials, the aptamers, developed by Dr. Yingfu Li, exhibited comparable efficacy against SARS-CoV-2 when measured against a commercial monoclonal antibody.

Thus, all the aforementioned factors are expected to boost the market over the forecast period. However, unfavorable pharmacokinetic properties of aptamers, a low awareness level, and incomplete regulatory policies may hamper the overall market growth.

Aptamers Industry Segmentation

As per the scope of the report, aptamers are short, single-stranded DNA or RNA (ssDNA or ssRNA) molecules, that can selectively bind to a specific target, including peptides, proteins, small molecules, carbohydrates, toxins, and even live cells. Aptamers assume various shapes, owing to their tendency to form helices or single-stranded loops. These molecules are extremely versatile and are used to bind targets with high specificity and selectivity. The aptamers market is segmented by type, application, and geography. By type, the market is segmented into nucleic acid and peptide. By application, the market is segmented as diagnostics, therapeutics, research and development, and other applications. By geography, the market is segmented as North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD) for the above segments.